SCHEMBL14719344

SCHEMBL14719344

CN(C)CC(=O)N(c1ccc(F)c(-c2nn(C)cc2-c2ccncc2)c1F)S(=O)(=O)c1cc(F)ccc1F

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 5/20 0.41
CSNK1E P49674 5/20 0.41
MAPK14 Q16539 3/20 0.41
MAPK13 O15264 2/20 0.41
MAPK12 P53778 2/20 0.41
MAPK11 Q15759 2/20 0.41
PDE10A Q9Y233 3/20 0.36
PDE4A P27815 2/20 0.36
PDE4B Q07343 2/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
BRAF P15056 8/20 0.35
SRC P12931 1/20 0.33
KDR P35968 1/20 0.33
MAPK3 P27361 2/20 0.32
MAPK1 P28482 2/20 0.32
KCNH2 Q12809 1/20 0.32
GRIN2B Q13224 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14719049 0.91 PDE10A (0.34) PDE10ABRAFMAPK3MAPK1
SCHEMBL14719043 0.91 BRAF (0.33) CSNK1DCSNK1EMAPK14MAPK13MAPK12
SCHEMBL14108508 0.89 CSNK1D (0.44) CSNK1DCSNK1EMAPK14MAPK13MAPK12
SCHEMBL2357435 0.89 CSNK1D (0.44) CSNK1DCSNK1EMAPK14MAPK13MAPK12
SCHEMBL2359967 0.88 MAPK14 (0.40) CSNK1DCSNK1EMAPK14MAPK13MAPK12
SCHEMBL2359173 0.87 CSNK1D (0.42) CSNK1DCSNK1EMAPK14MAPK13MAPK12
SCHEMBL2318653 0.87 PSEN1 (0.32) MAPK14MAPK13MAPK12MAPK11BRAF
SCHEMBL2317795 0.85 CSNK1D (0.47) CSNK1DCSNK1EMAPK14MAPK13MAPK12
SCHEMBL14719347 0.85 CSNK1D (0.38) CSNK1DCSNK1EMAPK14MAPK13MAPK12
SCHEMBL2358577 0.85 MAPK14 (0.39) CSNK1DCSNK1EMAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528909-B1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-06-22 EP claimed
US-8791265-B2 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-07-29 US claimed
EP-2528909-B1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-06-22 EP disclosed
US-8791265-B2 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-07-29 US disclosed
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K15, MAP3K19, CDK3 CSNK1D 316/4885CSNK1E 351/4885MAPK14 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.